Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

Inclusion Criteria:

- Diagnosis of PsA classified by CASPAR; Rheumatoid factor and anti-CCP antibodies
negative; diagnosis of active plaque psoriasis, with at least one psoriatic plaque of
≥2cm diameter or nail changes consistent with psoriasis or documented history of
plaque psoriasis; inadequate control of symptoms with NSAIDs; inadequate control of
symptoms with a conventional DMARD.

Exclusion Criteria:

- Pregnant or nursing women, evidence of ongoing infectious or malignant process;
previous exposure to any biologic drug for Psoriatic Arthritis or Psoriasis; subjects
taking high potency opioid analgesics; ongoing use of prohibited psoriasis treatments
/ medications; previous treatment with any cell-depleting therapies including but not
limited to anti-CD20, investigational agents.

Other protocol-defined inclusion/exclusion criteria may apply